Key Takeaway: Innate Pharma showcased initial Phase 1 clinical data for IPH4502 at the ENA 2026 conference. The data indicates positive early results, contributing to the ongoing development of this therapeutic candidate. This presentation marks a significant step in the drug's clinical evaluation.
Market Sentiment Analysis
POSITIVE FACTORS
Innate Pharma presented initial data for IPH4502.
The presentation occurred at ENA 2026.
Phase 1 clinical data shows promising results.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
7%
average across 4 past catalysts
Lead asset
IPH5201
Phase 2 · Non Small Cell Lung Cancer
Full Press Release Details
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Innate Pharma presents initial Phase 1 clinical data for IPH4502 at ENA 2026
Frequently Asked Questions
What is IPH4502?
IPH4502 is a therapeutic candidate developed by Innate Pharma.
Where was the data presented?
The initial Phase 1 data was presented at ENA 2026.
What phase is IPH4502 currently in?
IPH4502 is currently in Phase 1 clinical trials.
What were the results of the Phase 1 data?
The Phase 1 data showed promising initial results.